Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

Delayed Quote. Delayed  - 08/30 05:35:24 pm
14.875 GBp   +0.85%
07/28 PROTEOME SCIENC : Sales Momentum To Continue After Strong First Half
07/28 PROTEOME SCIENC : Trading Update and Notice of Results
06/24 PROTEOME SCIENC : AGM Statement and Result of AGM
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/23/2016 08/24/2016 08/25/2016 08/26/2016 08/30/2016 Date
14.875(c) 14.625(c) 14.75(c) 14.75(c) 14.875 Last
337 546 266 266 76 260 30 000 14 340 Volume
+3.48% -1.68% +0.85% 0.00% +0.85% Change
More quotes
Financials ( GBP)
Sales 2016 3,00 M
EBIT 2016 -2,60 M
Net income 2016 -2,50 M
Debt 2016 8,60 M
Yield 2016 -
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 -
Capi. / Sales2016 14,1x
Capi. / Sales2017 -
Capitalization 33,6 M
More Financials
Company
Proteome Sciences Plc engages in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.It focuses on developing proprietary protein biomarkers for neurological diseases,... 
More about the company
Latest news on PROTEOME SCIENCES PLC
07/28 PROTEOME SCIENCES : Sales Momentum To Continue After Strong First Half
07/28 PROTEOME SCIENCES : Trading Update and Notice of Results
06/24 PROTEOME SCIENCES : AGM Statement and Result of AGM
06/01 PROTEOME SCIENCES : Publication of Annual Reports and Accounts 2015
06/01 PROTEOME SCIENCES : CEO Appointment
05/18 PROTEOME SCIENCES : Appoints New CEO As Annual Loss Narrows
04/05 PROTEOME SCIENCES : Block Admission Report
04/05 PROTEOME SCIENCES : Welcomes Supportive Reports On Protein Profiling
04/05 PROTEOME SCIENCES : Deep Protein Profiling Key To Improving Cancer Treatment
02/29 PROTEOME SCIENCES : Starts 2016 Well, Production Capacity Up
More news
Sector news : Bio Therapeutic Drugs
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
More sector news : Bio Therapeutic Drugs
Advertisement
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Full-screen chart
Technical analysis trends PROTEOME SCIENCES...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Director
Christopher D. J. Pearce Executive Chairman
Ian H. Pike Chief Operating Officer & Executive Director
Geoffrey John Ellis Secretary, Executive & Finance Director
Malcolm Ward Chief Technical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-6.35%44
AMGEN, INC.5.66%128 351
GILEAD SCIENCES, INC.-22.75%103 158
CELGENE CORPORATION-9.86%83 674
REGENERON PHARMACEUTIC..-26.43%42 053
VERTEX PHARMACEUTICALS..-22.96%24 020
More Results